Synthesis and evaluation of isoxazole derivatives as lysophosphatidic acid (LPA) antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 13, 2007, Pages 3736-3740

  Yamamoto, Takashi ^a   Fujita, Koichi ^a   Asari, Sayaka ^a   Chiba, Akira ^a   Kataba, Yuka ^a   Ohsumi, Koji ^a   Ohmuta, Naoko ^a   Iida, Yuko ^a   Ijichi, Chiori ^a   Iwayama, Satoshi ^a   Fukuchi, Naoyuki ^a   Shoji, Masataka ^a  

^a AJINOMOTO CO INC   (Japan)

Author keywords

Isoxazole derivative; Liver fibrosis; LPA antagonists; Lysophosphatidic acid; Lysophosphatidic acid receptor (LPA1)

Indexed keywords

3 [4 [4 [1 (2 CHLOROCYCLOPENT 1 ENYL)ETHOXYCARBONYLAMINO]ISOXAZOL 3 YL]BENZYLSULFANYL]PROPIONIC ACID; ISOXAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN;

ANIMALS; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DESIGN; FIBROSIS; HUMANS; INHIBITORY CONCENTRATION 50; ISOXAZOLES; LIVER; LYSOPHOSPHOLIPIDS; PROPIONIC ACIDS; RATS;

EID: 34250181673     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.04.024     Document Type: Article

References (32)

1. Gerrard J.M., Kindom S.E., Peterson D.A., Peller J., Krantz K.E., and White J.G. Am. J. Pathol. 96 2 (1979) 423
2. Moolenaar W.H. Curr. Opin. Cell Biol. 7 (1995) 203
3. Feng L., Mills G.B., and Prestwich G.D. Expert Opin. Ther. Patents 13 10 (2003) 1619
4. Mills G.B., and Moolenaar W.H. Nat. Rev. Cancer 3 (2003) 582
5. Tokumura A., Iimori M., Nishioka Y., Kitahara M., Sakashita M., and Tanaka S. Am. J. Physiol. 267 (1994) C204
6. Seewald S., Sachinidis A., Dusing R., Ko Y., Seul C., Epping P., and Vetter H. Atherosclerosis 130 1-2 (1997) 121
7. Hla T., Lee M.J., Ancellin N., Paik J.H., and Kluk M.J. Science 294 (2001) 1875
8. Contos J.J.A., Ishii I., and Chun J. Mol. Pharmacol. 58 6 (2000) 1188
9. Noguchi K., Ishii S., and Shimizu T. J. Biol. Chem. 278 (2003) 25600
10. Chun J., Edward J.G., Hla T., Igarashi Y., Lynch K.R., Moolenaar W., Pyne S., and Tigyi G. Pharmacol. Res. 54 (2002) 265
11. McIntyre T.M., Pontsler A.V., Silva A.R., St Hilaire A., Xu Y., Hinshaw J.C., Zimmerman G.A., Hama K., Aoki J., Arai H., and Prestwich G.D. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 131
12. Ikeda H., Yatomi Y., Yanase M., Satoh H., Nishihara A., Kawabata M., and Fujiwara K. Biochem. Biophys. Res. Comm. 248 (1998) 436
13. Yanase M., Ikeda H., Matsui A., Maekawa H., Noiri E., Tomiya T., Arai M., Yano T., Shibata M., Ikebe M., Fujiwara K., Rojkind M., and Ogata I. Biochem. Biophys. Res. Comm. 277 (2000) 72
14. Tangkijvanich P., Melton A.C., Santiskulvong C., and Yee Jr. H.F. J. Biomed. Sci. 10 (2003) 352
15. Murata T., Arii S., Mori A., and Imamura M. J. Surg. Res. 114 (2003) 64
16. Takuwa Y., Takuwa N., and Sugimoto N. J. Biochem. 131 (2002) 767
17. Svetlov S.I., Sautin Y.Y., and Crawford J.M. Biochim. Biophys. Acta 1582 (2002) 251
18. Heise C.E., Santos W.L., Schreihofer A.M., Heasley B.H., Mukhin Y.V., Macdonald T.L., and Lynch K.R. Mol. Pharmacol. 60 6 (2001) 1173
19. Heasley B.H., Jarosz R., Carter K.M., Van S.J., Lynch K.R., and Macdonald T.L. Bioorg. Med. Chem. Lett. 14 (2004) 4069
20. Heasley B.H., Jarosz R., Lynch K.R., and Macdonald T.L. Bioorg. Med. Chem. Lett. 14 (2004) 2735
21. Durgam G.G., Virag T., Walker M.D., Tsukahara R., Yasuda S., Liliom K., van Meeteren L.A., Moolenaar W.H., Wilke N., Siess W., Tigyi G., and Miller D.D. J. Med. Chem. 48 15 (2005) 4919
22. Gududuru V., Zeng K., Tsukahara R., Makarova N., Fujiwara Y., Pigg K.R., Baker D.L., Tigyi G., and Miller D.D. Bioorg. Med. Chem. Lett. 16 2 (2006) 451
23. Durgam G.G., Tsukahara R., Makarova N., Walker M.D., Fujiwara Y., Pigg K.R., Baker D.L., Sardar V.M., Parrill A.L., Tigyi G., and Miller D.D. Bioorg. Med. Chem. Lett. 16 3 (2006) 633
24. Okusa M.D., Ye H., Huang L., Sigismund L., Macdonald T., and Lynch K.R. Am. J. Physiol. Renal Physiol. 285 (2003) F565
25. Yamada T., Sato K., Komachi M., Malchinkhuu E., Tobo M., Kimura T., Kuwabara A., Yanagita Y., Ikeya T., Tanahashi Y., Ogawa T., Ohwada S., Morishita Y., Ohta H., Im D.S., Tamoto K., Tomura H., and Okajima F. J. Biol. Chem. 279 8 (2004) 6595
26. Ueno, A.; Nagao, R.; Watanabe, T.; Ohta, H.; Yagi, M. European Patent 1,258,484, 2001.
27. Ohta H., Sato K., Murata N., Damirin A., Malchinkhuu E., Kon J., Kimura T., Tobo M., Yamazaki Y., Watanabe T., Yagi M., Sato M., Suzuki R., Murooka H., Sakai T., Nishitoba T., Im D.S., Nochi H., Tamoto K., Tomura H., and Okajima F. Mol. Pharmacol. 64 4 (2003) 994
28. Mukaiyama T., Narasaka K., and Banno K. Chem. Lett. (1973) 1011
29. Mukaiyama T., Narasaka K., and Banno K. J. Am. Chem. Soc. 96 (1974) 7503
30. 5-(4-Methyl-phenyl)-isoxazole-4-carboxylic acid methyl ester, model compound of the ester of isoxazole-4-carboxylate, was easily decomposed into 3-(4-methyl-phenyl)-2-cyano-3-hydroxy-acrylic acid with overnight treatment of 0.1 M NaOH aq/MeOH. Similar ring opening reaction was known in anti-inflammatory drug leflunomide. kalgutkar A.S., Nguyen H.T., Vaz A.D.N., Doan A., Dalvie D.K., McLeod D.D., and Murray J.C. Drug Metab. Dispos. 31 10 (2003) 1240 and references herein
31. 50 values represent the mean of not less than two different runs.
32. 50 values represent the mean of not less than two different runs